Didanosine
- Generic Name
- Didanosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N4O3
- CAS Number
- 69655-05-6
- Unique Ingredient Identifier
- K3GDH6OH08
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse tra...
- Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT00002429
- Locations
- 🇺🇸
NJCRI, Newark, New Jersey, United States
🇺🇸Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇨🇦Clinique Medicale L'Actuele, Montreal, Quebec, Canada
Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Research Institute for Genetic and Human Therapy
- Target Recruit Count
- 225
- Registration Number
- NCT00002427
- Locations
- 🇺🇸
Albany Med College, Albany, New York, United States
🇺🇸Boulevard Comprehensive Care Ctr, Jacksonville, Florida, United States
🇺🇸Gary Blick MD, Stamford, Connecticut, United States
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00002376
- Locations
- 🇺🇸
Kaiser Foundation Hospital, San Francisco, California, United States
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00002162
- Locations
- 🇺🇸
UCD Med Ctr, Sacramento, California, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸UCSD Treatment Ctr, San Diego, California, United States
Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- PharmaResearch
- Target Recruit Count
- 200
- Registration Number
- NCT00008489
- Locations
- 🇺🇸
George Washington Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸Park Nicollet Med Ctr / Hlth Education, St. Louis Park, Minnesota, United States
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002234
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
🇺🇸Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia and Upjohn
- Registration Number
- NCT00002123
- Locations
- 🇺🇸
Albany Med College, Albany, New York, United States
🇺🇸Univ of Maryland at Baltimore, Baltimore, Maryland, United States
🇺🇸Buckley Braffman Stern Med Associates, Philadelphia, Pennsylvania, United States
A Study of Nystatin in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Argus Pharmaceuticals
- Registration Number
- NCT00002313
- Locations
- 🇺🇸
Twelve Oaks Hosp, Houston, Texas, United States
A Study of MKC-442 in Combination With Other Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00002412
- Locations
- 🇺🇸
Dr Robert Wallace, St. Petersburg, Florida, United States
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00006208
- Locations
- 🇺🇸
East Bay Clinical Trial Ctr, Concord, California, United States
🇺🇸Orange Coast Med Group, Newport Beach, California, United States
🇺🇸Health Positive, Safety Harbor, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.